PT  - JOURNAL ARTICLE
AU  - Selene Manga
TI  - TB research and innovation in Latin America
AID  - 10.1183/16000617.0107-2020
DP  - 2021 Mar 31
TA  - European Respiratory Review
PG  - 200107
VI  - 30
IP  - 159
4099  - http://err.ersjournals.com/content/30/159/200107.short
4100  - http://err.ersjournals.com/content/30/159/200107.full
SO  - EUROPEAN RESPIRATORY REVIEW2021 Mar 31; 30
AB  - The production of tuberculosis (TB) research and innovation in Latin America during the past decade has notably improved. Its role in the acceleration of the decline of the average annual TB incidence rate by 2.5% from 2017 to 2018 is still unclear, but it is looking promising that the region will meet the End TB Strategy targets set for 2030. Well performed and high-quality research and evidence is critical for improving national TB control programme outcomes. In Latin America, this need is most apparent when responding to the multidrug-resistant TB epidemic.There is an urgent need for technological breakthroughs to accelerate by an average of 17% per year if the decline in TB incidence rate is to meet the target set for 2030. Intensified research and innovation, identified as one of the three essential pillars of the End TB Strategy, has scarcely been achieved in the region due to political and economic context. This will be analysed further in this article.The current epidemiological status of TB in Latin America, with its high morbidity and mortality due to TB and MDR-TB, does not match the development of R&D in TB and MDR-TB in the region https://bit.ly/3r3sv0F